22/08/2026
Policymakers will be left without the rigorous research that is desperately needed to elucidate both the potential risks and therapeutic effects of medical ma*****na
A proposed reclassification of medical ma*****na products as Schedule III drugs would address only two of the three key barriers to research on ma*****na’s safety and effectiveness for various indi...